Secukinumab
- PDF / 169,842 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 93 Downloads / 155 Views
1 S
Inflammatory bowel disease: case report A 54-year-old woman developed inflammatory bowel disease during treatment with secukinumab for chronic plaque psoriasis and psoriatic arthritis. The woman who had chronic plaque psoriasis and psoriatic arthritis presented with a one-month history of diarrhoea with accompanying urgency, tenesmus, abdominal discomfort and weight loss. She was a current smoker and had used NSAIDs in the past. Investigations showed an elevated level of faecal calprotectin with mildly elevated inflammatory markers including ESR and CRP. Her other investigations were unremarkable. Based on these findings and clinical presentation, she was referred for urgent colonoscopy, which revealed mild-to-moderate patchy ileal inflammation with ulcers. Reporting gastroenterologist suspected these findings as an indicative of inflammatory bowel disease, possibly induced by secukinumab. Fourteen months prior to symptoms onset, she was commenced on secukinumab for psoriatic arthritis and chronic plaque psoriasis [routes and dosage not stated]. As per the recommendation of gastroenterologist, secukinumab was discontinued. The woman remained off secukinumab for two months until worsening of psoriasis. During this period, her bowel symptoms significantly improved. This affirmed the diagnosis of secukinumab-induced inflammatory bowel disease. Thereafter, she was initiated on tildrakizumab for psoriasis. Following which, her chronic plaque psoriasis and psoriatic arthritis improved and she had complete resolution of inflammatory bowel disease. Additionally, her inflammatory markers normalised. Darch KM, et al. Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23. Case Reports in Medicine 2020: 2020. Available from: URL: http:// 803500452 doi.org/10.1155/2020/9404505
0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Sep 2020 No. 1821
Data Loading...
